• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.60
  • VXN 23.66
  • VXO 18.16
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

IMMU (Immunomedics Inc.)
Last Trade 18.09 Dividend/Share 0 PE Ratio -21.8
Date 12:13:36 PM Dividend Yield 0.000 Return on Assets -57.25
Change 0.07 ExDividend Date 0 Return on Capital null
Bid 17.95 Latest EPS -1.9 Price/Sale 3,838.287
Ask 18.01 LatestEPS Date 2018-06-30 Price to Book 9.69
Volume 64988 EPS ttm -0.830 Institutional % 108.1
Avg Volume 2.9M Shares Outstanding 190.43M Insider % 1.4
Open 18.25 Float 188.18M Short Ratio null
Prev Close 18.02 Return On Equity -158.22 5 Year Change % 2.161
High 18.51 Consensus EPS -0.2 2 Year Change % 3.632
Low 17.86 No. of Estimate 3.000 1 Year Change % 0.165
52 Week High 27.33 EPS Surprise $ null YTD Change % 0.203
52 Week Low 12.86 EPS Surprise Percent -70 6 Month Change % -0.293
52 Week Change 5.996 EBITDA 0M 3 Month Change % -0.108
50 Day MA 18.8091 Revenue 0M 1 Month Change % -0.038
200 Day MA Gross Profit 0M 5 Day Change % 0.045
Market Cap 3431.51M Cash 0M 30 Day Change % -0.103
Beta 2.246539 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.